From 100 to 600 patients: to support patients suffering from acne, Avène, Pierre Fabre Laboratories' leading brand, is strengthening the robustness of its clinical studies via data augmentation through Artificial Intelligence. TOULOUSE, France, March 11, 2026 -- Avène, the leading brand in French pharmacies*, in partnership with Toulouse-based HealthTech company BotDesign, has announced a major breakthrough in the field of clinical studies in dermo-cosmetics. In 2026, Avène will conduct a comparative clinical study to evaluate the efficacy of
Performers from the Got Talent universe will headline a new live stage show for families on Legend of the Seas, marking the global format's first-ever show at sea MIAMI, March 11, 2026 -- Royal Caribbean is making waves with the debut of a brand-new America's Got Talent stage show on Legend of the Seas. In August 2026, America's Got Talent LIVE on Legend of the Seas will deliver a reimagined extension of the beloved global variety show to families from around the world, marking the first time the series will headline at sea. "At Royal Caribbean, w
The world's leading next-generation sports tournament heads to Astana from 29 July to 9 August 2026, bringing together elite athletes and gamers to compete across groundbreaking hybrid disciplines. DUBAI, UAE, March 11, 2026 -- Phygital International, promoter and rights holder of the Games of the Future (GOTF), has officially confirmed that the Games of the Future 2026 will take place in Astana, Kazakhstan, from 29 July to 9 August 2026, bringing together the world's leading phygital athletes for 12 days of elite competition that uniquely blends physical sport and digital game
STOCKHOLM, March 11, 2026 -- Gesynta Pharma AB today announced that the first patient has been dosed in its Phase 2 clinical proof-of-concept trial (NOVA) of vipoglanstat, a novel non-hormonal, non-opioid drug candidate for endometriosis. This milestone marks an important step toward a new treatment for the approximately 190 million women worldwide living with this painful, often debilitating, chronic inflammatory condition, which is also a major cause of infertility. The NOVA* trial is a randomized, double-blind, placebo-controlled Phase 2 clinical proof-of-concept trial of vipoglanst
ST. PAUL, Minn., March 11, 2026 -- iotaMotion, Inc., the leader in robotic-assisted insertion systems for cochlear implantation and creator of iotaSOFT®, the first and only FDA cleared robotic-assisted cochlear implant insertion system, today announced the issuance of U.S. Patent No. 12,558,123, further strengthening its intellectual property portfolio in robotic-assisted cochlear implantation. "This new patent augments our strong intellectual property portfolio, which broadly covers systems and methods related to robotic positioning and control in cochlear implant sur
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, March 11, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Entrepreneurs First to join Taking Stock after the market close Kristen Scholer delivers the pre-market update on March 11th Equities remain choppy as the conflict in the Middle East continues and the International Energy Agency is proposing the biggest-in-history
TORONTO, March 11, 2026 -- Today, OPTrust released its 2025 Funded Status Report — Service & Security – Since 1995 — which details the Plan's financial results and funded status, while marking its 30th anniversary. In 2025, OPTrust remained fully funded for the 17th consecutive year and achieved a net investment return of 4.2 per cent. Over the past 10 years, the Plan's average net investment return is 6.7 per cent. "Thirty years ago, OPTrust was founded with a mission to pay pensions today, and preserve pensions for tomorrow," said Peter Lindley, President and CE
NEW YORK, March 11, 2026 -- DermRays, a pioneer in medical-grade consumer beauty technology, recently announced the global launch of the Lumenic™ Dual-Light & 3D-Oscillo™ System. This FDA-registered innovation is designed to disrupt the oral care market by offering a painless, professional-grade whitening and repair solution that fits into a daily brushing routine. As the demand for at-home cosmetic dentistry surges in North America and Europe, consumers often face a trade-off between effective whitening and tooth sensitivity. The Lumenic™ system eliminates this compromise
NEW YORK, March 11, 2026 -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean technology company believes that a window for earnings growth has opened with the continuous rise of the Baltic Dry Index (BDI), a leading indicator of the global dry bulk shipping market. The industry's rising prosperity evidenced by sustained freight rate hikes, expanded market demand and released profit elasticity, are expected to enhance the profit potential of HTCO's core business. The BDI is highly correlated with the operating performance of dry
NEW YORK, March 11, 2026 -- Millions of women worldwide live with Polycystic Ovary Syndrome (PCOS), a complex hormonal condition that remains widely underdiagnosed, stigmatized, and misunderstood. Beyond its medical implications, PCOS often affects mental health, self-esteem, and daily quality of life, particularly through visible symptoms such as excess hair growth. To help address these challenges through education, advocacy, and community support, Ulike has entered an official partnership with the PCOS Awareness Association (PCOSAA), a global nonprofit dedicated to empowering individuals w